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Background: Inflammatory bowel disease (IBD)-like conditions in glycogen storage disease (GSD) type Ib have
been predominantly described in children. Signs and symptoms of GSD type Ib are hypoglycemia, pancytopenia
and hepatosplenomegaly. Based on few published cases, there is evidence that granulocyte-colony stimulating
factor (G-CSF) in patients with glycogenosis–related pancytopenia might ameliorate the IBD-like disease through
leukocyte increase.
Case presentation: Here we firstly describe a case of an adult 33-year-old Caucasian male patient with GSD type Ib
accompanied with IBD-like disease with persistent pancytopenia despite moderate-dose G-CSF treatment. Recent
vomiting and abdominal discomfort were due to a high-grade stenosis in the transverse colon. A dose increase of
the G-CSF successfully normalized his leukocyte count. However, the stenosis worsened and surgical therapy was
needed.
Conclusion: We suggest that symptomatic patients with GSD type Ib should undergo endoscopic examination in
order to detect IBD-like disease and to initiate early treatment.
Keywords: Crohn’s disease, IBD-like disease, Stenosis, Glycogenosis, Glycogen storage disease, Granulocyte colony
stimulating factor, G-CSFBackground
Glycogen storage disease Ib (GSD Ib) is characterized
by deficiency of glucose-6-phosphate translocase (Gene:
SLC37A4) [1] inherited as an autosomal recessive trait.
Clinically the disease is characterized by deficient glyco-
genolysis resulting in hypoglycemia, hypertriglyceridemia,
phosphate deficiency and lactate acidosis and hepatosple-
nomegaly. Pancytopenia may occur with GSD Ib [2]. So
far, inflammatory bowel disease (IBD)-like conditions has
been predominantly described in children with GSD Ib
with mean age of approximately 5.9 years [3-5]. This case
reports of an adult 33-year-old man.Case presentation
Here we report a 33-year-old Caucasian man with GSD
Ib presented at our emergency room complaining of* Correspondence: britta.siegmund@charite.de
†Equal contributors
1Department of Medicine I (Gastroenterology, Rheumatology, Infectious
Diseases), Charité – Universitätsmedizin Berlin, Berlin, Germany
Full list of author information is available at the end of the article
© 2015 Volz et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.abdominal pain, nausea and vomiting. Onset of symptoms
was acute. The patient reported not to know similar
conditions before except diffuse pain due to hypoglycemia,
which he described differently. The patient had an irregular
heterozygous compound gene mutation (c.[1108_1109delCT
(;)1189 + 1G > C]; protein level: p.[Leuc370Valfs*53(;)];
in exons 10), suggestive to be disease relevant. No
other family member suffered from GSD. He reported
regular defecation of mushy consistency without blood
three times a day. Physical examination revealed in spite
of pronounced hepatomegaly and cachexia, normal oral
and anal mucosa as well as normal height and intelligence
(occupation: sales representative in the IT industry).
Despite regular cornstarch ingestion of 90 g/every 4 h, the
glucose concentration at first presentation was 34 mg/dl,
lactate concentration was 134 mg/dl (ULN = 20 mg/dl),
and C-reactive protein was 13.5 mg/l (ULN= 5 mg/l).
Even though the patient was on continuous granulocyte
colony stimulating factor (G-CSF) therapy (48 million
IU/every other day) leukopenia prevailed (leukocytes
0.93/nl, neutrophils 0.76/nl, hemoglobin 10.0 g/dl,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fusion improved his abdominal symptoms. A diagnostic
CT-scan to exclude ischemia demonstrated hepatospleno-
megaly, a feature of GSD Ib, and a short thickening of the
intestinal wall at the transverse colon (Figure 1A and B).
Ultrasound examination of the abdomen confirmed
the stenosis. At the location of the stenosis the entire
intestinal wall was 6 mm in diameter. There was no
intestinal wall vascularization, consistent with grade I
of IBD according to the Limberg classification [6]
(Figure 1C). A colonoscopy again revealed a short
stenosis in the transverse colon which could not be
passed with a 12.8 mm colonoscope (Figure 2A). The
stenosis appeared scarred with some inflammatory changes.
Histopathological examination of the biopsy showed
hyperplastic and polypoid mucosa. Gastroscopy of the
upper gastrointestinal tract was without pathologies. Due
to the severe leukopenia/neutropenia, immunosuppressive
medication, such as steroids or TNF-alpha antibodies,
was not considered a treatment option. Instead, we
increased the dosage of G-CSF to 30 million IU/d in
order to reach a higher leukocyte count and thus, to
control the mucosal inflammation. The decision was
based on evidence for a beneficial effect of G-CSF inA B
C
Figure 1 Radiographic pictures of the stenosis. 1A and 1B: CT-scan of
view). 1C: Ultrasound picture of the stenosis. Stenosis was 5.9 mm × 6.7 m
There was no intra- or extra-mural vascularization present consistent with lglycogenosis-associated IBD-like disease [3] as well as a
previous randomized controlled trial in patients with
Crohn’s disease showing that GM-CSF was able to
decrease disease activity and to improve quality of life [7].
After five weeks on high-dose G-CSF abdominal pain
had receded, yet defecation was still mushy. Leucocytes had
normalized (5-7/nl), while anemia and thrombocytopenia
persisted (hemoglobin: 11.8 g/dl (LLN= 13.5 g/dl); throm-
bocytes: 84/nl (LLN= 150/nl)). C-reactive protein (0.7 mg/l)
was normal as was calprotectin (<50 mg/kg). However,
colonoscopy revealed a progressive, predominantly
scarring stenosis with approximately 4 mm in diameter
(Figure 2B). Thus, surgical therapy was decided upon.
A laparoscopic segmental resection of the transverse
colon with end-to-end-anastomosis was performed.
The instantaneous section showed chronic, florid ulcerous
inflammation, hypertrophic muscular layer and massive
fibrosis consistent with a scarring stenosis. No signs of
malignancy were observed (Figure 3). Surgery was
complicated by insufficiency of the anastomosis
resulting in an intra-abdominal abscess and subsequent
surgery. Eighteen days after the second surgery the
patient could be discharged from the hospital on his
former G-CSF schedule.the stenosis of the transverse colon (1A: frontal view; 1B: horizontal
m in diameter. The intestinal wall appeared thickened and hypoechoic.
evel I according to the Limberg classification.
Figure 2 Endoscopic pictures of the stenosis. 2A: First colonoscopy with macroscopic inflammation. 2B: Second colonoscopy with
increased stenosis.
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We describe a case of an IBD-like disease in an adult
patient with GSD type Ib. This condition is caused by a
deficiency of the enzyme glucose-6-phosphate translocase
as well as pancytopenia [1,2]. To the best of our
knowledge, only few cases of IBD-like disease in GSD
type Ib, mainly in children, have been described so
far [5,8-14]. The patient in our case was 33-year-old
before he presented symptoms of an IBD-like disease.
This might be due to his continuous G-CSF treatment,
since neutrophil count has been maintained higher and
potentially delayed onset of IBD-like disease. On the
other hand, his irregular heterozygous compound
gene mutation could be an explanation why he got
symptomatic as an adult and not as a child. Overall,
IBD is thought to be associated with GSD type Ib, and
leukopenia/neutropenia may play a role in the pathogenesis
of intestinal inflammation [5]. This assumption is
supported by evidence that colony stimulating factors
can improve IBD-like disease in patients with GSD
type Ib [3,7,15,16]. In a previous report, it was shown
that G(M)-CSF not only increased neutrophil count,
but also improved intestinal inflammation as indicated
by radiological findings and clinical symptoms of two
young patients with GSD-associated IBD-like disease
[15]. The authors suggested that neutrophil deficiencyFigure 3 Histological picture. Pathological picture of instantaneous sectio
hypertrophy of the muscular layer and massive fibrosis consistent with a scmight contribute to the development of this phenotype by
facilitating acute and chronic infection in the gut mucosa
leading to subsequent inflammation [15]. Alternatively,
abnormal bowel metabolism resulting from translocase
deficiency in the mucosal cells may be an explanation. In
contrast to these previous reports, G-CSF did not improve
the IBD-like disease in the present case of an adult
patient suffering from GSD type Ib. Moreover, despite
a normalization of leucocytes/neutrophils in response
to the dose increase of G-CSF treatment, his abdominal
stenosis worsened. This may be due to i) the fact that
despite normalization of leukocyte counts, dysfunctional
glucose-6-phosphatase deficient neutrophils are less
effective in dealing with inflammatory processes [15], ii)
the acute inflammatory stage of the IBD-like disease had
already passed and a mainly scarring stenosis remained,
when the patient presented as indicated by the scarred
endoscopic and pathologic appearance.
Conclusion
Therefore, we suggest that even in adult patients with
GSD type Ib abdominal symptoms, normally interpreted as
related to hypoglycemia or lactate acidosis, should include
the differential diagnosis of an IBD-like disease. Immediate
abdominal ultrasound examination should be performed
followed by a colonoscopy in case of pathological findingsn showing chronic, florid ulcerous inflammation as well as a
arring stenosis.
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may allow appropriate treatment as soon as possible in the
course of disease and prevent surgical treatment.
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by the Editor of this journal. The CARE guidelines have
been used for this case report [17].
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